GAPDH and cancer: Considering these reports, LL-37 can be associated with dual aspects of cancer progression via various receptors, such as epidermal growth factor receptor (EGFR), FRP2, ERBb2, P2X7, and GAPDH, or suppression via interaction with peptide-based factors and cancer membrane components.